Mesalamine – USA

Mesalamine – USA

On Sep. 12, 2017, Northern District of West Virginia issued an opinion ruling that Mylan’s proposed generic version of Apriso® does not infringe the asserted patent(s).
Salix / Valeant Pharmaceuticals hold an approved New Drug Application (“NDA”) for Apriso® (Mesalamine) extended-release capsules.  It was approved by the United States Food and Drug Administration (“FDA”) on Oct 31, 2008. There are total 07 patents listed in orange book (OB) of which 6 are expiring on Apr 20, 2018 & one US 8,865,688 is expiring on May 1, 2030.
Mylan Pharmaceuticals filed Abbreviated New Drug Application (ANDA) to the FDA seeking approval to market a generic version of Apriso®.  Salix sued Mylan in Jun 2015 in Northern District of West Virginia & court held bench trial in March 2017. Court decided that plaintiffs have not carried their burden to prove that Mylan’s ANDA product will infringe claim 1 of the ‘688 Patent either directly or indirectly.
Lupin is the first ANDA filer for this product & has settled the case.  Other filers are Novel & Teva. Novel’s case was dismissed in Jul 2017 & Teva’s case is under discovery.

In a parallel PTAB proceeding, on Dec. 08, 2015, Generico LLC filed Inter Partes Review over the US’688 patent & Mylan joined this IPR. On May 19, 2017, the Patent Trial and Appeal Board of the USPTO issued its Final Written Decision in an IPR proceeding & held that two claims in dispute (1 and 16) of the US’688 patent were obvious in view of the prior arts. This decision is under appeal at CAFC.
Leave a Reply

Leave a Reply

Your email address will not be published.

Disclaimer
All content provided on this blog is for informational purposes only. By using the blog, you agree that the information on this blog does not constitute legal or other professional advice on author's or on his company's behalf.

Copyrights 2022 Pharma IP Circle. All Rights Reserved